Philadelphia- ACI Clinical has surpassed a new milestone of 50,000 adjudicated endpoints during the first quarter of 2017. The specialty adjudication company is pioneering adjudication practices beyond the traditional large cardiovascular outcome trials into a wide breadth of medical specialties with emerging needs for safety and efficacy endpoint evaluation.
Philadelphia – ACI Clinical, the leading independent specialty provider of Endpoint Adjudication and Data Monitoring Committees to the clinical trial industry, is proud to announce the addition of two new executives, Andrew MacKnight and Amit Bhattacharyya. Both are seasoned industry professionals with successful track records managing organizational growth. "Timing
ACI Clinical is pleased to be a sponsor at the upcoming 2016 Endpoint Adjudication Forum in Philadelphia on October 19-20, 2016. Highlights of the conference include a presentation and discussion on industry best practice, performance standards by ACI’s EAC Lead, Shaena Kaufman, on Wednesday, October 19 at 2:45 p.m.
PLYMOUTH MEETING, Pa. -- Pinnacle 21, the leading provider of clinical data standards software and subject matter expertise to the life sciences industry, today announced the availability of a comprehensive set of expert clinical data lifecycle services. Pinnacle 21, known for their Pinnacle 21 Enterprise software used by FDA,
ACI Clinical will participate in an expert think tank exploring The Role of Adjudication in Medical Device Clinical Trials. The meeting is scheduled for March 11, 2016, at the ACC Heart House in Washington, D.C. The one-day meeting is sponsored by the Cardiac Safety Research Consortium (CSRC) and the
From a technical perspective, the beginning of the clinical research process often brings to mind images of scientists in the lab. But long before a drug or device company begins the arduous and uncertain journey to develop a new therapy, it is the patients and their stories that inspire
The FDA released a new draft Drug Safety Guidance for Industry on December 16, 2015. The draft document recommends the use of special Safety Assessment Committees to oversee and report on patient safety data throughout a drug's development program. The intended impact is to improve patient safety through a
Strategic Planning for Expert Committees can save 40% in Endpoint Adjudication and Data Monitoring Costs
Philadelphia, PA – ACI Clinical (www.aciclinical.com), an industry leader in independent committee management, offers expert review of clients’ clinical research needs to develop comprehensive, strategic committee solutions across entire drug programs. These solutions leverage opportunities for cost savings and operational efficiencies by implementing committees on a more global scale
The New England Journal of Medicine today shared landmark results from the EMPA-REG OUTCOME trial. The study revealed a marked reduction in cardiovascular (CV) mortality and morbidity for high CV risk type 2 diabetes patients when taking empagliflozin (a sodium glucose cotransporter 2 inhibitor). Throughout the randomized, double-blind, placebo-controlled trial, all cardiovascular
ACI Clinical representatives participated in a Clinical Trials Transformation Initiative (CTTI) Expert Meeting on July 28-29, 2015, in Silver Spring, MD. The meeting served as part of an ongoing CTTI project to improve the quality and usage of DMCs. The two-day expert meeting brought together diverse clinical trials stakeholders,